Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Open Text Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287.95 (market cap $39.89B), while Open Text Corporation trades at $23.6 (market cap $5.56B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 7.2× Open Text Corporation's market cap, and Open Text Corporation pays a 4.78% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | OTEX | |
|---|---|---|
Market Cap | $39.89B | $5.56B |
Sector | Health | Technology |
52-Week High | $491.22 | $39.69 |
52-Week Low | $278.09 | $20.01 |
Enterprise Value | $38.15B | $10.72B |
Dividend Yield | — | 4.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
OTEX trades at $23.01, up 0.17% today, with a bullish technical signal from moving averages and a consensus analyst price target of $29.75 implying 29% upside. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.994 exceeding expectations, and maintains robust profitability with a 73.06% gross margin. Recent developments include a $105 million investment in European AI and cloud expansion and the divestiture of non-core assets.
The outlook is positive given undervalued metrics like a P/E of 11.17 and EV/EBITDA of 6.7, alongside strategic focus on AI and cloud growth. Risks include execution challenges in integrating new investments and competitive pressures in the tech sector. Investor sentiment is cautiously optimistic, supported by analyst upgrades and institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
